

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Chang

Art Unit: 1642

Application No. 09/701,536

Filed: June 18, 2001

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin

Date: July 21, 2003

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 21, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Tanya M. Harding, Ph.D.
Attorney for Applicant

RECEIVED
JUL 24 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file the IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please see the attached Transmittal Letter for Deposit Account authority.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number 6395-64907

Application Number 09/701,536

Filing Date June 18, 2001

First Named Inventor Chang

Art Unit 1642

Examiner Name Jeffrey S. Park

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 98/37911	Sept. 3, 1998	WIPO
		WO 99/06068	Feb. 11, 1999	WIPO

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Colombage <i>et al.</i> , "DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus," <i>Virology</i> 250:151-163, 1998
		Konishi <i>et al.</i> , "The Anamnestic Neutralizing Antibody Response Is Critical for Protection of Mice from Challenge following Vaccination with a Plasmid Encoding the Japanese Encephalitis Virus Premembrane and Envelope Genes," <i>J. Virology</i> 73(7):5527-5534, July 1999
		Konishi <i>et al.</i> , "A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice," <i>Vaccine</i> 18:1133-1139, 2000
		Porter <i>et al.</i> , "Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses," <i>Arch. Virol.</i> 143:997-1003, 1998
		Raviprakash <i>et al.</i> , "Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein," <i>Vaccine</i> 18:2426-2434, 2000
		Schimaljohn <i>et al.</i> , "Naked DNA Vaccines Expressing the prM and E Genes of Russian Spring Summer Encephalitis Virus and Central European Encephalitis Virus Protect Mice from Homologous and Heterologous Challenge," <i>J. Virology</i> 71(12):9563-9569, December 1997
		Wang <i>et al.</i> , "Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein," <i>J. Immunol.</i> 167:5273-5277, 2001

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.